Julio C Chavez, Farah Yassine, Jose Sandoval-Sus, Mohamed A Kharfan-Dabaja
{"title":"Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.","authors":"Julio C Chavez, Farah Yassine, Jose Sandoval-Sus, Mohamed A Kharfan-Dabaja","doi":"10.2217/ijh-2020-0021","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL).</p><p><strong>Methods: </strong>Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL.</p><p><strong>Results: </strong>Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50-83%, 83-93% and 93%, respectively.</p><p><strong>Conclusions: </strong>Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/cf/ijh-10-33.PMC8445151.pdf","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2020-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10
Abstract
Aims: To review recent data and relevant of the role of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin lymphoma (NHL).
Methods: Review and compilation of the most recent and relevant data published in full text and abstract forms of anti-CD19 CAR T-cell therapy for B-cell NHL.
Results: Different anti-CD19 CAR T-cell therapy products have been tested and shown significant clinical activity across B-cell NHL patients. The objective responses in relapsed DLBCL, FL and MCL were 50-83%, 83-93% and 93%, respectively.
Conclusions: Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.
目的:回顾抗cd19嵌合抗原受体(CAR) t细胞治疗b细胞非霍奇金淋巴瘤(NHL)的最新数据和相关作用。方法:回顾和汇编最近发表的有关抗cd19 CAR - t细胞治疗b细胞NHL的全文和摘要形式的相关数据。结果:不同的抗cd19 CAR - t细胞治疗产品已经过测试，并在b细胞NHL患者中显示出显着的临床活性。复发的DLBCL、FL和MCL的客观有效率分别为50-83%、83-93%和93%。结论:抗cd19 CAR - t细胞疗法是治疗低风险难治性b细胞nhl的可行选择。
期刊介绍：
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
